Chapter 31. To Market, To Market - 1998
1999; Elsevier BV; Linguagem: Inglês
10.1016/s0065-7743(08)60593-x
ISSN1557-8437
Autores Tópico(s)Sexual function and dysfunction studies
ResumoThis chapter presents an overview of the new therapeutic chemical entities (NCEs), introduced in the markets in the year 1998. The number of new NCEs introduced into the world market for the first time in 1998 was 27, the fewest during the nineties. This represented a marked decrease from 39 in 1997, 38 in 1996, 35 in 1995, 44 in the record-breaking year of 1994, 43 in 1993, 36 in 1992, and 1991. With 16 NCE launches, the US was by far the most common first market for the new introductions. Switzerland was second with 4 NCEs launched, followed by Germany and Japan with 3, then Finland and Mexico with 2 new introductions. Among the NCEs launched for the first time in 1998, several were the first in class or with a novel mechanism of action. Viagra (Sildenafil), often proclaimed as the new active molecule of the year, was introduced as an orally-active potent inhibitor of PDE5 isozymes for the treatment of male erectile dysfunction. Xenical (Orlistat) was another major high profile launch. The only anti-HIV introduced in 1998 was Sustiva (Efavirenz), a non-nucleoside reverse transcriptase inhibitor.
Referência(s)